Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Sep;25(3):561-567.
doi: 10.1038/s41391-022-00517-6. Epub 2022 Feb 28.

Germline alterations among Hispanic men with prostate cancer

Affiliations
Multicenter Study

Germline alterations among Hispanic men with prostate cancer

Elizabeth Pan et al. Prostate Cancer Prostatic Dis. 2022 Sep.

Erratum in

  • Correction: Germline alterations among Hispanic men with prostate cancer.
    Pan E, Shaya J, Madlensky L, Randall JM, Javier-Desloges J, Millard FE, Rose B, Parsons JK, Nielsen SM, Hatchell KE, Esplin ED, Nussbaum RL, Weise N, Murphy J, Martinez ME, McKay RR. Pan E, et al. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):599. doi: 10.1038/s41391-022-00539-0. Prostate Cancer Prostatic Dis. 2022. PMID: 35488122 No abstract available.

Abstract

Background: Little is known about the true rate of pathogenic (P)/likely pathogenic (LP) germline alterations in Hispanic men with prostate cancer as most studies analyzing the prevalence of P/LP germline alterations were performed in a largely non-Hispanic white population (NHW).

Methods: We performed a retrospective analysis of two separate cohorts of men with prostate cancer: (1) a multicenter cohort of 17,256 men who underwent germline testing in a CLIA-certified laboratory and (2) a single-center cohort of all men eligible for germline testing between 2018 and 2020. The proportions of P/LP alterations and variants of uncertain significance (VUS) were computed. Fisher's exact test was used to compare germline alteration rates for significance. A multivariate logistic regression was performed adjusting for demographic and clinical factors to examine factors associated with germline testing.

Results: In the multicenter cohort, the rate of P/LP germline alterations among self-reported Hispanic men was 7.1%, which was lower than self-reported NHW men (9.7% vs. 7.1%, p = 0.058), but was not statistically significant. The VUS rate was significantly higher among the Hispanic cohort (21.5% vs. 16.6%, p = 0.005). In the single-center cohort, 136 Hispanic patients were eligible for testing of which 34 underwent germline testing (26.1%, N = 34/136). Of all prostate cancer patients in the single-center cohort undergoing germline testing (n = 173), the rate of P/LP alterations in Hispanic patients was not significantly different compared to NHW patients (14.7% vs. 12.2%, p = 0.77). The rate of VUS in Hispanic patients was significantly higher than that of NHW patients (20.6% vs. 7.2%, p = 0.047).

Conclusion: The P/LP germline alteration rate in our cohorts was similar between Hispanic and NHW men. The rate of VUS was significantly higher in Hispanic men, a consequence of undertesting in minority populations. These data support that Hispanic men with prostate cancer should be screened for germline testing similar to NHW men.

PubMed Disclaimer

References

    1. Cancer.org. 2021. Key statistics for prostate cancer | prostate cancer facts. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html . Accessed 27 Aug 2021.
    1. Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity—United States, 2001–2017. MMWR Morb Mortal Wkly Rep. 2020;69:1473–80. - DOI
    1. Dobbs RW, Malhotra NR, Abern MR, Moreira DM. Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis. Prostate Cancer Prostatic Dis. 2019;22:159–67. - DOI
    1. Miller KD, Ortiz AP, Pinheiro PS, Bandi P, Minihan A, Fuchs HE, et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J Clin. 2021;71:466–87. - DOI
    1. Brandão A, Paulo P, Teixeira MR. Hereditary predisposition to prostate cancer: from genetics to clinical implications. Int J Mol Sci. 2020;21:5036. - DOI

Publication types

LinkOut - more resources